



## Current Perceptions of Travellers' Diarrhoea Treatments and Vaccines: Results From a Postal Questionnaire Survey and Physician Interviews

Nicholas Miller, PhD,\* and Ingelise Saunders, BPharm<sup>†</sup>

\*Beremans Ltd, Cambridge, UK; <sup>†</sup>ACE Biosciences AS, Odense, Denmark

*Some of the data from this study have been presented at the Vaccine Development and Commercialisation Conference, May 23–24, 2006, Philadelphia, USA.*

### Abstract:

**Background.** Travellers' diarrhoea (TD) occurs at high frequency in individuals from industrialised countries visiting destinations in nonindustrialised countries and may result in chronic complications such as Guillain–Barré syndrome.

**Methods.** We distributed a questionnaire requesting information on physicians' perceptions of currently available TD products, hypothesised TD vaccines, and aspects of travellers' behavior. Some physicians also were interviewed by telephone.

**Results.** We obtained completed questionnaires from named individuals at 68 UK/US clinics. These individuals reported seeing a total of approximately 76,500 travellers per year, and estimated that 61% (UK) and 77% (US) of travellers present 2 weeks or more predeparture. More US (92%) than UK (43%) travellers are advised to purchase TD products. In both countries, 85% of travellers would be prescribed an ideal TD vaccine, but only ~47% (UK) and ~65% (US) would purchase this vaccine. About 80% of physicians would recommend an hypothesized 100% effective *Campylobacter* vaccine for travellers visiting regions where 30% of TD cases are caused by *Campylobacter*.

**Conclusions.** Physicians support the concept of TD vaccines, including campylobacteriosis vaccines. An ideal TD vaccine might be purchased by up to 16% (UK) and 28% (US) of relevant travellers. A 100% effective *Campylobacter* vaccine might be purchased by over 2 million UK/US travellers per year.

Full text: <http://www.blackwell-synergy.com/doi/abs/10.1111/j.1708-8305.2007.00118.x>